GHR and hepatocellular carcinoma: In fact, treatment with FDA-approved GHR antagonist, Pegvisomant, effected a 2-fold reduction in the EC50 of doxorubicin against human HCC cells irrespective of exogenous GH treatment (Supplementary Figure 3).